Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques.

Marthas ML, Van Rompay KK, Abbott Z, Earl P, Buonocore-Buzzelli L, Moss B, Rose NF, Rose JK, Kozlowski PA, Abel K.

Vaccine. 2011 Apr 12;29(17):3124-37. doi: 10.1016/j.vaccine.2011.02.051. Epub 2011 Mar 4.

2.

Emergence of simian immunodeficiency virus-specific cytotoxic CD4+ T cells and increased humoral responses correlate with control of rebounding viremia in CD8-depleted macaques infected with Rev-independent live-attenuated simian immunodeficiency virus.

von Gegerfelt A, Valentin A, Alicea C, Van Rompay KK, Marthas ML, Montefiori DC, Pavlakis GN, Felber BK.

J Immunol. 2010 Sep 15;185(6):3348-58. doi: 10.4049/jimmunol.1000572. Epub 2010 Aug 11.

3.

Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV.

Van Rompay KK, Abel K, Earl P, Kozlowski PA, Easlick J, Moore J, Buonocore-Buzzelli L, Schmidt KA, Wilson RL, Simon I, Moss B, Rose N, Rose J, Marthas ML.

Vaccine. 2010 Feb 10;28(6):1481-92. doi: 10.1016/j.vaccine.2009.11.061. Epub 2009 Dec 6.

4.

The use of nonhuman primate models in HIV vaccine development.

Morgan C, Marthas M, Miller C, Duerr A, Cheng-Mayer C, Desrosiers R, Flores J, Haigwood N, Hu SL, Johnson RP, Lifson J, Montefiori D, Moore J, Robert-Guroff M, Robinson H, Self S, Corey L.

PLoS Med. 2008 Aug 12;5(8):e173. doi: 10.1371/journal.pmed.0050173. No abstract available.

5.

Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.

Van Rompay KK, Durand-Gasselin L, Brignolo LL, Ray AS, Abel K, Cihlar T, Spinner A, Jerome C, Moore J, Kearney BP, Marthas ML, Reiser H, Bischofberger N.

Antimicrob Agents Chemother. 2008 Sep;52(9):3144-60. doi: 10.1128/AAC.00350-08. Epub 2008 Jun 23.

6.

Developing a neonatal HIV vaccine: insights from macaque models of pediatric HIV/AIDS.

Marthas ML, Miller CJ.

Curr Opin HIV AIDS. 2007 Sep;2(5):367-74. doi: 10.1097/COH.0b013e3282cecf21.

PMID:
19372914
7.

Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.

Van Rompay KK, Johnson JA, Blackwood EJ, Singh RP, Lipscomb J, Matthews TB, Marthas ML, Pedersen NC, Bischofberger N, Heneine W, North TW.

Retrovirology. 2007 Apr 6;4:25.

8.

Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge.

Florese RH, Van Rompay KK, Aldrich K, Forthal DN, Landucci G, Mahalanabis M, Haigwood N, Venzon D, Kalyanaraman VS, Marthas ML, Robert-Guroff M.

J Immunol. 2006 Sep 15;177(6):4028-36.

9.
10.

Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus.

Van Rompay KK, Kearney BP, Sexton JJ, Colón R, Lawson JR, Blackwood EJ, Lee WA, Bischofberger N, Marthas ML.

J Acquir Immune Defic Syndr. 2006 Sep;43(1):6-14.

PMID:
16810108
11.

Long lasting control and lack of pathogenicity of the attenuated Rev-independent SIV in rhesus macaques.

von Gegerfelt AS, Alicea C, Valentin A, Morrow M, van Rompay KK, Ayash-Rashkovsky M, Markham P, Else JG, Marthas ML, Pavlakis GN, Ruprecht RM, Felber BK.

AIDS Res Hum Retroviruses. 2006 Jun;22(6):516-28.

PMID:
16796527
12.

Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques.

Van Rompay KK, Singh RP, Heneine W, Johnson JA, Montefiori DC, Bischofberger N, Marthas ML.

J Virol. 2006 Jul;80(13):6399-410.

13.

Rapid virus dissemination in infant macaques after oral simian immunodeficiency virus exposure in the presence of local innate immune responses.

Abel K, Pahar B, Van Rompay KK, Fritts L, Sin C, Schmidt K, Colón R, McChesney M, Marthas ML.

J Virol. 2006 Jul;80(13):6357-67.

14.

Role of CD8+ cells in controlling replication of nonpathogenic Simian Immunodeficiency Virus SIVmac1A11.

Van Rompay KK, Blackwood EJ, Landucci G, Forthal D, Marthas ML.

Virol J. 2006 Apr 3;3:22.

16.

Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV.

Van Rompay KK, Abel K, Lawson JR, Singh RP, Schmidt KA, Evans T, Earl P, Harvey D, Franchini G, Tartaglia J, Montefiori D, Hattangadi S, Moss B, Marthas ML.

J Acquir Immune Defic Syndr. 2005 Feb 1;38(2):124-34.

PMID:
15671796
17.

Rapid dissemination of SIV following oral inoculation.

Milush JM, Kosub D, Marthas M, Schmidt K, Scott F, Wozniakowski A, Brown C, Westmoreland S, Sodora DL.

AIDS. 2004 Dec 3;18(18):2371-80.

PMID:
15622313
18.

Tenofovir primes rhesus macaque cells in vitro for enhanced interleukin-12 secretion.

Van Rompay KK, Marthas ML, Bischofberger N.

Antiviral Res. 2004 Aug;63(2):133-8.

PMID:
15302142
19.

Support for the RV144 HIV vaccine trial.

Belshe R, Franchini G, Girard MP, Gotch F, Kaleebu P, Marthas ML, McChesney MB, McCullough R, Mhalu F, Salmon-Ceron D, Sekaly RP, van Rompay K, Verrier B, Wahren B, Weissenbacher M.

Science. 2004 Jul 9;305(5681):177-80; author reply 177-80. No abstract available.

PMID:
15247455
20.

The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters.

Van Rompay KK, Singh RP, Brignolo LL, Lawson JR, Schmidt KA, Pahar B, Canfield DR, Tarara RP, Sodora DL, Bischofberger N, Marthas ML.

J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):900-14.

PMID:
15220696
21.

CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.

Van Rompay KK, Singh RP, Pahar B, Sodora DL, Wingfield C, Lawson JR, Marthas ML, Bischofberger N.

J Virol. 2004 May;78(10):5324-37.

22.

Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques.

Van Rompay KK, Brignolo LL, Meyer DJ, Jerome C, Tarara R, Spinner A, Hamilton M, Hirst LL, Bennett DR, Canfield DR, Dearman TG, Von Morgenland W, Allen PC, Valverde C, Castillo AB, Martin RB, Samii VF, Bendele R, Desjardins J, Marthas ML, Pedersen NC, Bischofberger N.

Antimicrob Agents Chemother. 2004 May;48(5):1469-87. Erratum in: Antimicrob Agents Chemother. 2994 Jan;48(6):2346.

23.

Immunoprophylaxis to prevent mother-to-child transmission of HIV-1.

Safrit JT, Ruprecht R, Ferrantelli F, Xu W, Kitabwalla M, Van Rompay K, Marthas M, Haigwood N, Mascola JR, Luzuriaga K, Jones SA, Mathieson BJ, Newell ML; Ghent IAS Working Group on HIV in Women Children.

J Acquir Immune Defic Syndr. 2004 Feb 1;35(2):169-77. Review.

PMID:
14722451
24.

Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.

Vogel TU, Reynolds MR, Fuller DH, Vielhuber K, Shipley T, Fuller JT, Kunstman KJ, Sutter G, Marthas ML, Erfle V, Wolinsky SM, Wang C, Allison DB, Rud EW, Wilson N, Montefiori D, Altman JD, Watkins DI.

J Virol. 2003 Dec;77(24):13348-60.

26.

Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251.

Van Rompay KK, Greenier JL, Cole KS, Earl P, Moss B, Steckbeck JD, Pahar B, Rourke T, Montelaro RC, Canfield DR, Tarara RP, Miller C, McChesney MB, Marthas ML.

J Virol. 2003 Jan;77(1):179-90.

27.

Topical administration of low-dose tenofovir disoproxil fumarate to protect infant macaques against multiple oral exposures of low doses of simian immunodeficiency virus.

Van Rompay KK, Schmidt KA, Lawson JR, Singh R, Bischofberger N, Marthas ML.

J Infect Dis. 2002 Nov 15;186(10):1508-13. Epub 2002 Oct 29.

PMID:
12404171
28.

Decreased levels of recent thymic emigrants in peripheral blood of simian immunodeficiency virus-infected macaques correlate with alterations within the thymus.

Sodora DL, Milush JM, Ware F, Wozniakowski A, Montgomery L, McClure HM, Lackner AA, Marthas M, Hirsch V, Johnson RP, Douek DC, Koup RA.

J Virol. 2002 Oct;76(19):9981-90.

30.

Anatomic site and immune function correlate with relative cytokine mRNA expression levels in lymphoid tissues of normal rhesus macaques.

Abel K, Alegria-Hartman MJ, Zanotto K, McChesney MB, Marthas ML, Miller CJ.

Cytokine. 2001 Dec 7;16(5):191-204.

PMID:
11814315
31.

Rev-independent simian immunodeficiency virus strains are nonpathogenic in neonatal macaques.

von Gegerfelt AS, Liska V, Li PL, McClure HM, Horie K, Nappi F, Montefiori DC, Pavlakis GN, Marthas ML, Ruprecht RM, Felber BK.

J Virol. 2002 Jan;76(1):96-104.

32.
33.

Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection.

Van Rompay KK, McChesney MB, Aguirre NL, Schmidt KA, Bischofberger N, Marthas ML.

J Infect Dis. 2001 Aug 15;184(4):429-38. Epub 2001 Jul 16.

PMID:
11471100
34.

Route of simian immunodeficiency virus inoculation determines the complexity but not the identity of viral variant populations that infect rhesus macaques.

Greenier JL, Miller CJ, Lu D, Dailey PJ, Lü FX, Kunstman KJ, Wolinsky SM, Marthas ML.

J Virol. 2001 Apr;75(8):3753-65.

35.

Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.

Van Rompay KK, Miller MD, Marthas ML, Margot NA, Dailey PJ, Canfield DR, Tarara RP, Cherrington JM, Aguirre NL, Bischofberger N, Pedersen NC.

J Virol. 2000 Feb;74(4):1767-74.

36.

Isolation and partial characterization of a lentivirus from talapoin monkeys (Myopithecus talapoin).

Osterhaus AD, Pedersen N, van Amerongen G, Frankenhuis MT, Marthas M, Reay E, Rose TM, Pamungkas J, Bosch ML.

Virology. 1999 Jul 20;260(1):116-24.

37.

9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA.

Van Rompay KK, Cherrington JM, Marthas ML, Lamy PD, Dailey PJ, Canfield DR, Tarara RP, Bischofberger N, Pedersen NC.

Antimicrob Agents Chemother. 1999 Apr;43(4):802-12.

38.

Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies.

Tarantal AF, Marthas ML, Shaw JP, Cundy K, Bischofberger N.

J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Apr 1;20(4):323-33.

PMID:
10096575
39.

Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques.

van Rompay KK, Dailey PJ, Tarara RP, Canfield DR, Aguirre NL, Cherrington JM, Lamy PD, Bischofberger N, Pedersen NC, Marthas ML.

J Virol. 1999 Apr;73(4):2947-55.

40.
41.

Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection.

Van Rompay KK, Berardi CJ, Aguirre NL, Bischofberger N, Lietman PS, Pedersen NC, Marthas ML.

AIDS. 1998 Jun 18;12(9):F79-83.

PMID:
9662190
42.

Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques.

Van Rompay KK, Marthas ML, Lifson JD, Berardi CJ, Vasquez GM, Agatep E, Dehqanzada ZA, Cundy KC, Bischofberger N, Pedersen NC.

AIDS Res Hum Retroviruses. 1998 Jun 10;14(9):761-73.

PMID:
9643376
43.

Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection.

Van Rompay KK, Berardi CJ, Dillard-Telm S, Tarara RP, Canfield DR, Valverde CR, Montefiori DC, Cole KS, Montelaro RC, Miller CJ, Marthas ML.

J Infect Dis. 1998 May;177(5):1247-59.

PMID:
9593009
44.
45.

Antiretroviral drug trials.

Van Rompay KK, Marthas ML.

Science. 1997 Jun 6;276(5318):1482-4. No abstract available.

PMID:
9190679
46.

A zidovudine-resistant simian immunodeficiency virus mutant with a Q151M mutation in reverse transcriptase causes AIDS in newborn macaques.

Van Rompay KK, Greenier JL, Marthas ML, Otsyula MG, Tarara RP, Miller CJ, Pedersen NC.

Antimicrob Agents Chemother. 1997 Feb;41(2):278-83.

47.

9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques.

Van Rompay KK, Cherrington JM, Marthas ML, Berardi CJ, Mulato AS, Spinner A, Tarara RP, Canfield DR, Telm S, Bischofberger N, Pedersen NC.

Antimicrob Agents Chemother. 1996 Nov;40(11):2586-91.

48.

Localization of simian immunodeficiency virus nucleic acid and antigen in brains of fetal macaques inoculated in utero.

Lane JH, Tarantal AF, Pauley D, Marthas M, Miller CJ, Lackner AA.

Am J Pathol. 1996 Oct;149(4):1097-104.

49.

Fetal or neonatal infection with attenuated simian immunodeficiency virus results in protective immunity against oral challenge with pathogenic SIVmac251.

Otsyula MG, Miller CJ, Tarantal AF, Marthas ML, Greene TP, Collins JR, van Rompay KK, McChesney MB.

Virology. 1996 Aug 1;222(1):275-8.

50.

Vaccination of pregnant macaques protects newborns against mucosal simian immunodeficiency virus infection.

Van Rompay KK, Otsyula MG, Tarara RP, Canfield DR, Berardi CJ, McChesney MB, Marthas ML.

J Infect Dis. 1996 Jun;173(6):1327-35.

PMID:
8648204

Supplemental Content

Loading ...
Support Center